Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q3 2021 Earnings Presentation

35 slides from Walgreens Boots Alliance's earnings presentation, Jul 1, 2021

  1. Slide 1: Fiscal 2021 Third Quarter Results

    Fiscal 2021 Third Quarter Results July 1, 2021 © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 1

  2. Slide 2: Safe harbor and non-GAAP

    Safe harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not historical including, without limitation, estimates of and goals for future operating, financial and tax performance and results, including our f

  3. Slide 3: Introduction

    Introduction • Delivered a very strong quarter • Alliance Healthcare divestiture is complete • Strong execution in the administration of COVID-19 vaccines in the U.S. • Continued investments to innovate for the future © 2021 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor an

  4. Slide 4: Playing a key role in pandemic recovery

    Playing a key role in pandemic recovery >25m vaccinations administered to date 95% of Walgreens locations administering vaccines Vaccinations >1,100 off-site clinics in medically underserved communities >9m tests since pandemic onset Trained pharmacy staff; expanded testing capabilities to ~6k locat

  5. Slide 5: WBA Financial Performance

    WBA Financial Performance © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 5

  6. Slide 6: 3Q financial highlights

    3Q financial highlights • Total adjusted EPS $1.51; exceeded expectations ⎯ +81.4% above prior year in constant Fx • Continuing operations adjusted EPS $1.38 ⎯ +93.6% above prior year in constant Fx ⎯ Includes benefit from COVID-19 • Strong cash generation year-to-date ⎯ Operating cash flow $4.3bn ⎯

  7. Slide 7: 3Q financial highlights

    3Q financial highlights Results Reported Fx Constant Fx 3Q21 $ in millions (except EPS) B/(W) vs. 3Q20 B/(W) vs. 3Q20 Sales (continuing) $34,030 + 12.1% + 10.4% Operating income GAAP $1,134 + $2,817 (continuing) Adjusted $1,459 + 82.9% + 82.4% EPS - total GAAP $1.38 + $3.33 Adjusted $1.51 + 83.4% +

  8. Slide 8: Year-to-date FY21 financial highlights

    Year-to-date FY21 financial highlights Results Reported Fx Constant Fx YTD21 $ in millions (except EPS) B/(W) vs. YTD20 B/(W) vs. YTD20 Sales (continuing) $98,247 + 7.2% + 6.1% Operating income GAAP $1,432 + $1,058 (continuing) Adjusted $3,881 + 4.2% + 3.9% EPS - total GAAP $2.21 + $2.12 Adjusted $4

  9. Slide 9: United States – financials

    United States – financials Continuing operations $ in millions 3Q21 B/(W) vs. 3Q20 YTD21 B/(W) vs. YTD20 Sales $28,743 + 5.1% $83,250 + 3.1% Adj. gross profit $6,149 + 14.5% $17,525 + 2.9% Adj. SG&A % of sales 16.8% - 0.2%p 17.0% 0.0%p Adj. operating income $1,471 + 50.3% $3,789 + 2.3% Adj. operatin

  10. Slide 10: United States – pharmacy

    United States – pharmacy 3Q 3Q YTD YTD 3Q21 vs. 3Q20 Total Comparable Total Comparable Pharmacy sales + 6.3% + 8.4% + 5.1% + 6.0% Prescriptions + 8.7% + 9.8% + 2.3% + 3.8% • 3Q Rx script comp. grew +9.8% boosted by COVID-19 immunizations ~+6% ⎯ COVID-19 vaccinations 17 million in the quarter • Pharm

  11. Slide 11: United States – retail

    United States – retail 3Q YTD 3Q21 vs. 3Q20 Total retail sales + 1.4% - 2.6% Comparable retail sales + 1.7% - 0.5% • 3Q comp. retail sales +1.7%; excluding tobacco & e-cig. +2.6%, improving sequentially ⎯ Weak cough, cold and flu ebbs and mass personalization boosts results ⎯ Store traffic accelerat

  12. Slide 12: International – financials

    International – financials Continuing operations Constant Fx Constant Fx $ in millions 3Q21 B/(W) vs. 3Q20 YTD21 B/(W) vs. YTD20 Sales $5,288 + 58.7% $14,998 + 28.3% Adj. gross profit $1,060 + 38.6% $3,129 + 0.0% Adj. SG&A % of sales 18.3% + 9.2%p 18.7% + 6.7%p Adj. operating income $94 + $222 $326

  13. Slide 13: Boots UK – financials

    Boots UK – financials 3Q YTD 3Q21 vs. 3Q20 (constant Fx) Pharmacy comp. sales + 3.7% + 3.1% Retail comp. sales + 38.7% - 3.2% • Pharmacy comp. sales +3.7%; demand for additional services and favorable NHS funding phasing more than offset lower prescription volume • Phased reopening of UK high street

  14. Slide 14: Cash flow

    Cash flow B/(W) $ in millions YTD21 vs. YTD20 Operating cash flow $4,310 $912 Cash capital expenditure $1,001 ($39) Free cash flow $3,309 $873 • Strong free cash flow generation up +36% vs. prior year ₋ Reflects strong operating profit performance and continued focus on working capital, led by payme

  15. Slide 15: Fiscal year 2021 guidance

    Fiscal year 2021 guidance • Completed the divestiture of Alliance Healthcare • Maintaining TCMP goal of delivering in excess of $2bn in annual cost savings by FY22 • 3Q especially strong ⎯ Year-ago quarter exceptionally weak due to the peak of pandemic and “stay-at-home” restrictions ⎯ Retail recove

  16. Slide 16: Fiscal year 2021 guidance

    Fiscal year 2021 guidance Constant currency continuing operations adj. EPS growth: ~10% • Raising guidance from mid-to-high single digit to ~10% adj. EPS growth • Key swing factors: ₋ Vaccinations: now expecting 28 million driven by strong execution ₋ COVID-19 recovery and lapping prior year PPE ₋ I

  17. Slide 17: Strategic Initiatives

    Strategic Initiatives © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 17

  18. Slide 18: U.S. Pharmacy initiatives

    U.S. Pharmacy initiatives • Redefining operations with iA Rx automation ⎯ Automated micro-fulfillment centers operating in Phoenix & Dallas will soon ramp to serve ~1,000 locations ⎯ Best in class efficiency while unlocking the pharmacist time ⎯ Next nine markets identified for deployment by end of

  19. Slide 19: U.S. Retail initiatives

    U.S. Retail initiatives • Customer Engagement Platform learnings enhancing personalized offerings ⎯ myWalgreens membership +34% vs. prior quarter to ~75m members to date ⎯ Mass personalization boosted 3Q retail sales comps by ~100bps • Omni-channel offerings resonating & building momentum ⎯ Curbside

  20. Slide 20: International initiatives

    International initiatives • Launching innovative digital healthcare services ⎯ Boots Health Hub providing a marketplace for Boots and third-party online healthcare services ⎯ Boots ONLINE DOCTOR launched; delivering a market leading proposition for >40 conditions with more to come • Strong market sh

  21. Slide 21: © 2021 Walgreens Boots Alliance, Inc. All rights reserved. © 2020 Walgreens Boots Alliance,

    © 2020 Walgreens Boots Alliance, Inc. All rights reserved. © 2021 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on page 2 and endnotes on page 22 Confidential and Proprietary information. For internal use only. 21

  22. Slide 22: Endnotes

    Endnotes • Unless otherwise noted, all prior year numbers have been recast for continuing operations. Refer to WBA's Current Report on Form 8-K filed on March 31, 2021. • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures ◦ The company presents certain inf

  23. Slide 23: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente

  24. Slide 24: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended May 31, Change vs. 3Q20 Nine months ended May 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent Net Ear

  25. Slide 25: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended May 31, Change vs. 3Q20 Nine months ended May 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent Adjustm

  26. Slide 26: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended May 31, Change vs. 3Q20 Nine months ended May 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent Net ear

  27. Slide 27: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended May 31, Change vs. 3Q20 Nine months ended May 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Perc

  28. Slide 28: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Company’s proportionate share of non-GAAP adjustments reported by AmerisourceBergen consisten

  29. Slide 29: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2021 Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 28,743 $ 5,288 $ — $ 34,030 Gross p

  30. Slide 30: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) Three months ended May 31, 2020 (in millions) Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 27,357 $ 3,008 $ — $ 30,364 Gross p

  31. Slide 31: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Nine months ended May 31, 2021 Supplemental Information (unaudited) Walgreens Boots (in millions) United States1 International Corporate and Other Alliance, Inc. Sales $ 83,250 $ 14,998 $ — $ 98,247 Gross p

  32. Slide 32: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) Nine months ended May 31, 2020 (in millions) Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 80,734 $ 10,878 $ — $ 91,612 Gross p

  33. Slide 33: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS (LOSS) IN AMERISOURCEBERGEN Three months ended May 31, Nine months ended May 31, 2021 2020 2021 2020 Equity earnings in AmerisourceBergen (

  34. Slide 34: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended May 31, 2021 Three months ended May 31, 2020 Earnings before Earnings before income tax Income tax Effective

  35. Slide 35: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended May 31, Nine months ended May 31, 2021 2020 2021 2020 Net cash provided by operating activities (GAAP) 1 $ 1,754 $ 914 $

Walgreens Boots Alliance — Q3 2021 Earnings Presentation on 6ix